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Abstract
Background and Objectives Many studies and systematic reviews have estimated the healthcare costs of diabetes using a 
cost-of-illness approach. However, in the studies based on this approach patients’ heterogeneity is rarely taken into account. 
The aim of this study was to stratify patients with type 2 diabetes into homogeneous cost groups based on demographic and 
clinical characteristics.
Methods We conducted a retrospective cost-of-illness study by linking individual data on health services utilization retrieved 
from the administrative databases of Emilia-Romagna Region (Italy). Direct medical costs (either all-cause or diabetes-
related) were calculated from the perspective of the regional health service, using tariffs for hospitalizations and outpatient 
services and the unit costs of prescriptions for drugs. The determinants of costs identified in a generalized linear regression 
model were used to characterize subgroups of patients with homogeneous costs in a classification and regression tree analysis.
Results The study population consisted of a cohort of 101,334 patients with type 2 diabetes, followed up for 1 year, with a 
mean age of 70.9 years. Age, gender, complications, comorbidities and living area accounted significantly for cost variabil-
ity. The classification tree identified ten patient subgroups with different costs, ranging from a median of €483 to €39,578. 
The two subgroups with highest costs comprised dialysis patients, and the largest subgroup (57.9%) comprised patients 
aged ≥ 65 years without renal, cardiovascular and cerebrovascular complications.
Conclusions Classification of patients into homogeneous cost subgroups can be used to improve the management of, and 
budget allocation for, patients with type 2 diabetes.
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Key Points for Decision Makers 
Patients with type 2 diabetes differ on comorbid condi-
tions and complications.
There is no ‘average’ patient with diabetes.
The stratification into ten subgroups proposed in this 
paper may support clinicians in implementing effective 
preventive interventions and policy makers in designing 
resource allocation tailored to patients’ needs.
1 Introduction
Diabetes mellitus (DM) is a major public health prob-
lem with a high morbidity and mortality burden and high 
healthcare costs [1–3]. The International Diabetes Fed-
eration estimated that, in 2017, 451 million people were 
living with diabetes worldwide, and this figure is expected 
to increase to 693 million by 2045 [4] due to population 
growth, population aging, fast urbanization, excessive 
caloric intake and sedentary behaviors [5].
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Type 2 diabetes (T2DM) is the most prevalent type of 
diabetes, affecting almost 90% of people with diabetes [6].
In Italy, it has been estimated that the prevalence of 
DM in 2016 was 6.3%, and that one in five people were 
not diagnosed [7].
The total global healthcare expenditure for people with 
diabetes aged 18–99 years was estimated at US$850 bil-
lion in 2017 and is expected to increase by 7% by 2045 
[4]. In 2017, the North American and Caribbean Region 
accounted for 52% of the total amount spent worldwide 
on diabetes and the Europe Region accounted for a large 
share of the total global spending (26%), with a mean 
expenditure of 3432 international dollars [4]. In 2045, it 
is expected that healthcare costs for diabetes will remain 
stable for the population under the age of 50 years, but will 
increase by 37% for the population above 70 years [8]. The 
principal cost components are hospital and outpatient care, 
even if drug costs are becoming more relevant since the 
introduction of the expensive analog insulins and incretin-
based agents and sodium–glucose cotransporter 2 (SGLT-
2) inhibitors [9]. Many studies and systematic reviews 
[8, 10–17] have evaluated healthcare costs incurred by a 
population with diabetes using a cost-of-illness approach 
that includes all direct and indirect costs related to lost 
productivity. A recent systematic review [3] showed that 
the annual direct costs of diabetes per patient in interna-
tional dollars, regardless of the costing method applied and 
the cost components included, range from $242 in Mexico 
in 2010 [18] to $11,917 in a study conducted in the USA in 
2007 [19], while indirect costs range from $45 for Pakistan 
in 2006 [20] to $16,914 for the Bahamas in 2000 [21].
A recent study by Marcellusi et al. [22] reported that 
the total economic burden of patients with diabetes in Italy 
accounts for €20.3 billion/year, of which 54% is attribut-
able to indirect costs and 46% to direct costs. It has been 
estimated that in Italy the mean annual healthcare cost for 
patients with diabetes is about €3000 [7, 21, 23, 24]; that 
is more than twice that of patients without diabetes.
Converging evidence from different studies suggests 
that few patients with great clinical complexity account 
for a large part of diabetes-related costs [10, 11]. In fact, 
diabetes complications, in particular, those due to micro-
vascular and macrovascular damage (eye, renal and cardio-
vascular complications) account for a large proportion of 
healthcare expenditure [6, 10, 11, 25, 26], and comorbidi-
ties not directly related to diabetes also contribute to the 
economic burden of this condition [25, 27, 28].
Given the heterogeneity of patients with T2DM in terms 
of age, complications and comorbid conditions, the aim 
of the present study was to estimate, in a geographical 
area of North-Eastern Italy, the annual medical costs of 
T2DM, either all-cause or diabetes-related, and to stratify 
patients into different cost groups based on demographic 
and clinical characteristics. The Italian National Health 
System (NHS) provides universal coverage for all its citi-
zens and funds each Regional Health System, which pays 
for almost all medical costs, except for the small part of 
the costs of drugs and services that are co-paid by patients. 
People with diabetes are exempt from co-paying. In this 
context, the identification of patient subgroups with similar 
healthcare needs and clinical complexity could be useful to 
improve quality and cost control and to provide effective 
and cost-effective healthcare interventions and implement 
a payment system based on a tailored budget perspective, 
as applied in other countries.
2  Methods
We conducted a prevalence-based cost-of-illness study using 
a comprehensive global bottom-up approach to calculate the 
direct medical costs incurred by the NHS for patients with 
T2DM over 1 year.
The comprehensive approach, which incorporates costs 
attributable and non-attributable to T2DM diabetes, provides 
an accurate description of medical expenditure because dia-
betes is a chronic disease frequently affected by complica-
tions and comorbid conditions.
2.1  Data Source
Patient data including healthcare use (outpatient and inpa-
tient care) and drugs were obtained by linking data from 
different regional administrative databases using a unique 
anonymized patient identifier.
The hospital discharge record (HDR) database includes 
demographic characteristics, admissions and discharge 
dates, the main and up to five secondary diagnoses and up 
to six interventions [identified using the International Clas-
sification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) coding system]. In Italy, HDRs are a reliable 
and accurate source of hospital data based on the diagnosis-
related group (DRG) system that is used to allocate funds 
to hospitals and to monitor quality of care and outcomes at 
the national level.
The outpatient pharmaceutical database includes infor-
mation on patients’ gender and age, prescriptions [sub-
stance name, Anatomical Therapeutic Chemical (ATC) 
classification system code-V.2013, trade name, date of 
prescription filling, and number of packages]. This data-
base includes drugs reimbursed by the healthcare system 
that are prescribed by the general practitioner (GP) or 
a specialist. Drug prescriptions are tracked in the AFT 
(outpatient pharmaceutical supply) and FED (direct supply 
drugs) databases.
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The outpatient services database (ASA) includes labora-
tory tests, diagnostic, therapeutic and rehabilitation services 
and specialty visits, but does not include primary care visits, 
that cannot be traced.
Demographic information was retrieved from the differ-
ent sources (HDR, ASA, AFT, and FED).
2.2  Study Population
The study population included adult patients with T2DM 
living in three Local Health Authorities (LHAs) of Emilia-
Romagna Region (Italy), comprising about 2 million people. 
Patients were identified in 2014 through a regional algorithm 
[24] that combined information from different administra-
tive databases (hospital admissions, outpatient care, drug 
prescriptions, exemption for disease) and LHA data. In par-
ticular, we selected patients who in 2014 met at least one of 
the following criteria:
• Hospital discharge with ICD-9 CM primary or secondary 
diagnosis of diabetes (code 250.XX).
• At least two consecutive prescriptions of drugs for dia-
betes classified with the ATC classification system (code 
A10).
• Exemption from co-payment healthcare costs for DM.
Patients alive on 1/1/2015 were followed up to 
31/12/2015 to collect health services use and calculate the 
related annual direct medical costs. Subjects with missing 
data were excluded. Comorbidities were tracked from drug 
prescriptions in the previous year using an algorithm devel-
oped by Maio et al. [29], and complications in the previous 
3 years were retrieved from the HDR database and classified 
according to a regional dossier [24].
2.3  Outcomes
The outcomes of interest were the annual healthcare service 
use (outpatient and inpatient care and drug treatment) and 
costs of health services provided to patients with T2DM 
over the year 2015.
2.4  Costs
To calculate the annual medical costs for each patient with 
T2DM, we multiplied the number of services used by the 
respective unit cost. We used DRG tariffs as a proxy of 
costs for hospital admissions (http://salut e.regio ne.emili 
a-romag na.it/sisep s/sanit a/sdo/files /DGR_1673_2014.pdf/
view), the regional nomenclator (http://salut e.regio ne.emili 
a-romag na.it/docum entaz ione/nomen clato re-tariff ario -rer) 
for specialty visits and the unit cost of prescriptions for 
medications.
2.5  Statistical Analysis
Categorical variables were summarized using frequencies 
and percentages, and continuous variables using mean, 
standard deviation, median and range.
A generalized linear model (GLM) with gamma prob-
ability distribution and log link was used to investigate the 
determinants of costs. In this model, costs were regressed 
on gender, age group (under 65 years, between 65 and 
75 years, over 75 years), LHA of residence (Bologna, Parma, 
Modena), duration of illness (less than 1 year, between 1 
and < 5 years, 5 years or more), complications in the previ-
ous 3 years (coma, ischemic heart disease, stroke, periph-
eral revascularization, amputation, eye complications, renal 
complications and dialysis) and number of comorbidities 
(none, one, two, three or more), detected through drug pre-
scriptions. The goodness of fit of the model was measured 
using the predictive ratio, which is calculated as the ratio of 
predicted costs to observed costs. The value of the predictive 
ratio is always positive, with a value closer to one indicating 
higher predictive performance.
Then a classification and regression tree (CART) model 
[30] was used to stratify patients into homogeneous sub-
groups of costs based on demographic and clinical char-
acteristics. This method offers advantages with respect to 
other classification methods such as logistic regression or 
cluster analysis because it relies on assumptions about the 
type of relationship between the outcome and the explana-
tory variables, can handle multicollinearity among explana-
tory variables by selecting the best splitter and deals easily 
with interactions among variables [31].
The independent variables used in the CART were the 
same as those included in the GLM, except for the number 
of comorbidities. This was done because more than 90% 
of patients had at least one comorbidity derived from drug 
prescriptions, and some of these (gastrointestinal and mus-
culoskeletal) were very common and non-specific, thereby 
hindering the creation of distinct subgroups.
The CART selects in an automated way from the set of 
variables the one most associated with costs, and uses it to 
divide the population into two subgroups. If the independent 
variable is continuous (such as age), the procedure iden-
tifies a specific cut-off that maximizes the cost difference 
between two subgroups. If the independent variables con-
sist of more than two categories, the categories are merged 
to optimize the distinction into subgroups. Dichotomous 
variables are used as such by the procedure. The procedure 
continues recursively, selecting the second best variable 
and subdividing each subgroup recursively into two further 
subgroups and so on, until no significant improvement in 
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the classification of participants is possible. The maximum 
depth that can be achieved in the tree, i.e., maximum num-
ber of subsequent divisions, is five. An internal validation 
of the CART was conducted using a split-sample approach, 
in which the tree was first generated using a training sam-
ple, including 50% randomly selected cases, and then tested 
for classification accuracy in the remaining 50% of cases. 
Moreover, the tree was pruned to avoid overfitting the model. 
The tree’s predictive accuracy was measured using the risk 
estimate that denotes the within-node variance. A low risk 
estimate indicates node homogeneity.
Statistical analyses were performed using IBM SPSS, 
version 25.
3  Results
Through the database linkage we identified 102,638 patients 
with T2DM at 1/1/2015, of which 1304 were excluded, 
because of missing data. The final study population therefore 
includes 101,334 patients
Table 1 describes the characteristics of the study popula-
tion. Patients had a mean age of 70.9 years and a slight pre-
dominance of males (54.1%); 72.8% had diabetes for at least 
5 years; 65.6% had two or more comorbidities and 77.0% 
had no complications in the previous 3 years. Almost all 
patients were taking medications or had received outpatient 
care, and one in five was hospitalized during the follow-up.
The total costs for diabetic patients incurred in 2015 by 
the three LHAs (Table 2) show a skewed frequency distri-
bution, with a median value of €1012 and a mean value of 
€3086. Hospitalizations, drugs and outpatient care accounted 
for 53.1%, 29.5% and 17.4% of the total cost, respectively.
In the GLM estimating the total costs as a function 
of sociodemographic and clinical variables (Table  3), 
all independent variables were statistically significant 
(p < 0.001). Annual costs were higher in males, in patients 
aged more than 65 years compared with younger patients, 
and increased with the number of comorbidities. In addi-
tion, the complications that were the most relevant driv-
ers of costs were dialysis (b = 2.165, 95% CI 2.045–2.286; 
p < 0.001), peripheral revascularization (b = 0.494, 95% CI 
0.387–0.600; p < 0.001), renal complications (b = 0.470, 
95% CI 0.427–0.514; p < 0.001), coma (b = 0.369, 95% 
CI 0.304–0.434; p < 0.001), and ischemic heart disease 
(b = 0.317, 95% CI 0.289–0.344; p < 0.001).
Notably, costs were also higher for newly diagnosed 
patients compared with those of patients with an established 
diagnosis and for patients living in the Parma LHA as com-
pared with those living in Bologna or Modena LHAs.
In the CART model, the costs estimated by the GLM 
were used as the dependent variable. This procedure initially 
split the study population into two subgroups based on age 
Table 1  Characteristics of the study population (N = 101,334)
SD standard deviation
a 116 missing values
N %
Gender
Female 46,538 45.9
Male 54,796 54.1
Age (mean ± SD) 70.9 ± 12.8
Age group
< 65 29,937 29.5
65–74 29,351 29.0
≥ 75 42,046 41.5
Length of illness
< 1 year 7370 7.3
≥ 1 year to < 5 years 20,147 19.9
≥ 5 years 73,817 72.8
No. of complications in 2012–2014
0 78,011 77.0
1 17,849 17.6
2 4225 4.2
3 or more 1249 1.2
Coma 1319 1.3
Ischemic heart disease 8676 8.6
Stroke 5952 5.9
Peripheral revascularization 495 0.5
Amputation 384 0.4
Dialysis 381 0.4
Other renal complications 3153 3.1
Eye complications 9936 9.8
No. of comorbidities in 2012–2014a
0 9824 9.7
1 25,002 24.7
2 26,992 26.6
3 or more 39,470 39.0
Comorbidities in the last 3 years
Cancer 4907 4.8
Eye 9146 9.0
Gastrointestinal 43,592 43.0
Genitourinary 1314 1.3
Hematological 3345 3.3
Hepatobiliary 267 0.3
Immunologic 281 0.3
Male genital 11,396 11.2
Musculoskeletal 30,291 29.9
Neurologic 10,072 9.9
Psychological 18,149 17.9
Respiratory 11,562 11.4
Skin 1181 1.2
Cardiovascular 81,253 80.2
Death 4116 4.1
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(< 65 years and ≥ 65 years) and created further subdivisions 
using five variables (dialysis, ischemic heart disease, renal 
complications, stroke and duration of illness) to reach ten 
final homogeneous cost subgroups. The other complications, 
including coma, peripheral revascularization, amputation 
and eye complications, did not enter the model. The train-
ing and the test sample yielded overlapping results. The risk 
coefficient was low (0.126, with a standard error of 0.001) 
Table 2  Summary of direct medical costs
AFT outpatient pharmaceutical supply database, ASA outpatient services database, ATC Anatomical Therapeutic Chemical, FED direct supply 
drugs database, HDR hospital discharge record, SD standard deviation
a Lab tests and specialty visits
b Including diabetes drugs
Patients Median (€) Mean (€) SD (€) Min (€) Max (€) Sum (€) %
N %
Hospitalizations (HDR) 22,937 22.6 4221.4 7236.3 8884.2 70.0 193,830.7 165,980,102 53.1
Outpatient  carea (ASA) 94,915 93.7 262.0 572.3 2253.6 1.1 64,496.0 54,321,811 17.4
Diabetes drugs (ATC A10) 87,613 86.5 71.7 183.2 265.4 0.0 3419.4 16,047,912 5.1
All drugs (AFT + FED)b 99,845 98.5 514.4 925.7 3453.8 0.0 246,620.9 92,424,247 29.5
Total 101,334 100 1012.6 3086.1 7085.9 1.3 252,361.7 312,726,161 100
Table 3  Predictors of overall 
costs. Results of the generalized 
linear model. The predictive 
ratio is 1.011, denoting a good 
concordance between predicted 
and observed costs
CI confidence interval, LHA Local Health Authority, SE standard error
b SE (b) P 95% CI
Lower limit Upper limit
Constant 7.180 0.0191 < 0.001 7.143 7.218
Male gender 0.136 0.0076 < 0.001 0.121 0.151
Age groups
< 65 years (Reference category)
65–74 years 0.190 0.0100 < 0.001 0.171 0.210
≥ 75 years 0.177 0.0096 < 0.001 0.159 0.196
LHA of residence
Parma (Reference category)
Bologna −0.044 0.0103 0.001 −0.064 −0.024
Modena −0.056 0.099 < 0.001 −0.075 −0.036
Length of illness
< 1 years (Reference category)
≥ 1 and < 5 years −0.228 0.0164 < 0.001 −0.260 −0.196
≥ 5 years −0.139 0.0149 < 0.001 −0.169 −0.110
Number of comorbidities in the last 3 years
0 (Reference category)
1 0.270 0.0145 < 0.001 0.242 0.298
2 0.584 0.0146 < 0.001 0.555 0.613
≥ 3 1.000 0.0143 < 0.001 0.972 1.028
Complications in the last 3 years
Coma 0.369 0.0333 < 0.001 0.304 0.434
Ischemic heart disease 0.317 0.0140 < 0.001 0.289 0.344
Stroke 0.156 0.0164 < 0.001 0.124 0.188
Peripheral revascularization 0.494 0.0544 < 0.001 0.387 0.600
Amputation 0.419 0.0617 < 0.001 0.298 0.540
Eye complications 0.172 0.0127 < 0.001 0.147 0.197
Dialysis 2.165 0.0614 < 0.001 2.045 2.286
Renal complications 0.470 0.0220 < 0.001 0.427 0.514
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both in the training and in the test sample, denoting a good 
fit to the data. We report here the findings related to the test 
sample, which comprises 50% of cases (Fig. 1).
The empirical costs in euro in the final ten subgroups 
of the test sample ranged from a median of €483 to 
€39,578 (Table 4). The two subgroups with the highest cost 
(> €31,000), which comprise 0.3% of the population, con-
sisted of dialysis patients, regardless of age and the pres-
ence of ischemic heart disease. Groups B, C, E, F and L, 
comprising 14% of cases, with median cost ranging between 
€1415 and €3303, included patients with ischemic heart dis-
ease, renal disease or stroke. Group I, which was the largest 
(57.9%), included subjects aged 65 years or over without 
complications, with a median cost of €1054. The last two 
groups, which together comprised about one fourth of the 
cases (27.8%), consisted of subjects aged less than 65 years 
and with a duration of illness ≥ 5 years or < 1 year (median 
cost €720) or a duration of illness between 1 and 4 years 
(median cost €483).
4  Discussion
In this cost-of-illness study we analyzed the annual direct 
medical costs of a population of patients with T2DM com-
prising over 70% elderly, a large majority (72.9%) with a 
duration of illness > 5 years, and 65.6% with two or more 
chronic conditions.
The mean annual medical cost per capita was €3086, 
consistent with the results of other studies conducted in 
Italy or in Europe [7, 8, 11, 23, 32]. However, the median 
annual medical cost (€1012) is a more accurate summary 
measure because the distribution of costs is skewed, with 
a few patients accounting for a large proportion of costs, in 
line with other studies [10, 12]. We confirmed that hospi-
talization accounts for the large majority of costs (53.1%) 
followed by drugs (29.5%) and outpatient services (17.4%) 
[7, 8, 11, 23].
Our results support the evidence [6, 10–12, 25, 33] 
that the most relevant cost drivers are age, complications 
and comorbidities. Duration of illness had an independent 
association with costs. In fact, we found that medical costs 
are higher in the first year of diagnosis. It is reasonable to 
assume that in the first year of illness, resource consumption 
and access to healthcare services are more relevant [14] for 
diagnosis and staging in order to identify the best therapeutic 
strategies. Notably, the area of residence was associated with 
different costs, after adjusting for patients’ demographic and 
clinical characteristics, suggesting a role of organizational 
factors that warrants further investigation.
Through CART analysis we identified ten homogeneous 
subgroups of patients, five aged < 65 years and five aged 
65 years or more. The large majority (85.7% of the study 
population) fell into three subgroups including elderly or 
younger patients without ischemic heart disease, renal com-
plications, stroke and not on dialysis, with annual median 
costs < €1055. Five patient groups with higher costs, up to 
€3303, were characterized by the presence of at least one 
complication. Dialysis, which represents the end stage of 
chronic kidney disease, was the most expensive intervention 
and was delivered to a small minority of patients (0.3%) with 
annual costs amounting to more than €31,000.
These results suggest that preventive interventions are 
required to control the increasing prevalence of the disease, 
due to the aging population, and the rate of complications.
In this way, we could improve not only the health status 
of T2DM patients but also the amount of their medical costs 
[34, 35]. Because the natural process of ageing cannot be 
controlled, the focus of interventions should be mainly on 
correcting unhealthy behaviors related to poor diet or sed-
entary lifestyles to prevent both the onset of diabetes and 
its related complications [36, 37]. Concerning hospitaliza-
tions, which accounted for the majority (53.1%) of costs, a 
possible strategy would be to reduce those potentially pre-
ventable through more appropriate management of patients’ 
follow-up [6] and of drug treatments. In particular, some 
studies highlighted that the use of some SGLT-2 inhibitors 
compared with placebo could lead to a significant reduc-
tion in the hospitalization for heart failure, which is one of 
the major causes of admission to hospital in patients with 
T2DM [38, 39]. Our results concerning the costs of chronic 
kidney disease are consistent with other reports showing 
that, starting from stage 3A, the financial burden of chronic 
kidney disease increases as renal function declines [40, 41]. 
This supports early identification and clinical interventions 
for chronic kidney disease in patients with diabetes to delay 
progression towards end-stage renal failure through optimal 
management strategies [42].
Given the budget constraints and the need to allocate 
healthcare resources in an equitable way, our stratification 
of T2DM patients into cost subgroups could inform treat-
ment decisions and the allocation of related resources in 
a way that matches patients’ needs. Our results are useful 
especially because of the growing importance of the budget 
allocation from the perspective of activity-based provider 
payment systems [43], bundle payments and value-based 
bundle payments [44].
The results of the present study should be interpreted in 
light of strengths and limitations. To the best of our knowl-
edge this is the first study to stratify T2DM patients into 
cost subgroups based on demographic and clinical charac-
teristics using a classification tree approach. This procedure 
allows us to define subgroups of patients with combinations 
of demographic and clinical characteristics, while in gen-
eral, stratification is performed using only one criterion. 
For instance, another Italian study applied a cost-of-illness 
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approach to administrative data and stratified the patient 
population according to the number of comorbidities [22]. 
Thus, our results can provide useful insights as regards the 
implementation of healthcare policies and the organization 
of healthcare services.
Fig. 1  Classification and 
regression tree based on the 
testing sample that comprises 
50% of the study population 
(N = 50,799). Boxes include 
the absolute and percentage 
frequency of subgroups and the 
histogram of the cost distribu-
tion. The final nodes are marked 
in red
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In addition, the study is population-based, so it has no 
selection bias or external validity limitations. Moreover, 
it takes advantage of the linkage of individual data from 
high-quality administrative databases [45]. The inclusion 
criteria for this study have been validated in other studies 
[24, 46].
The implications of our study need to be interpreted 
also in light of some limitations. First, microcosting was 
not possible. In fact, we used tariffs that do not represent 
the real cost for the local health authority, but only the 
amount of money the LHA reimburses to providers. Sec-
ond, in this study, we did not estimate indirect costs for 
patients and caregivers. In Italy, information on productiv-
ity losses and out-of-pocket expenditure is not available at 
the patient level, but more research should be conducted to 
acquire these data, as social costs associated with diabetes 
are substantial. Third, it is possible that people suffering 
from T2DM are untreated and therefore are not captured 
by administrative databases.
Our results can be generalized to the other Italian regions 
because people with diabetes are exempt from co-payment 
of health services across the country and costs of drugs and 
outpatient and inpatient care are set at the national level, 
with small regional variations related to local agreements. 
Moreover, the methodology is replicable in other countries 
where the availability of administrative healthcare databases 
allows the reconstruction of the care pathway of patients 
with T2DM.
In conclusion, this study provides policy makers and 
clinicians relevant information about the cost of T2DM 
care based on patients’ demographic and clinical charac-
teristics. This information, combined with available data 
on epidemiological trends, may support clinicians in imple-
menting effective healthcare interventions (e.g., prevention 
of complications and associated comorbidities) and policy-
makers in designing resource allocation tailored to patients’ 
needs.
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Table 4  Median empirical costs of the 10 subgroups identified using classification and regression tree analysis. Subgroups are arranged in 
decreasing order of costs
CI confidence interval, SD standard deviation
Patients in 
the subgroup
Age Costs per patient (€)
N % Mean SD Median 95% CI lower limit 95% CI upper limit
D ≥ 65 years, dialysis, no ischemic cardiopathy 99 0.2 76.2 7.2 39,578.66 34,247.69 43,757.97
A < 65 years, dialysis 30 0.1 56.2 5.7 31,490.53 22,852.99 52,325.34
E < 65 years, renal complications, no ischemic cardiopathy 132 0.3 55.8 7.2 3303.67 2031.39 4605.30
F ≥ 65 years, renal complications, no dialysis, no ischemic 
cardiopathy
918 1.8 80.7 7.8 2465.96 2163.13 2930.63
B ≥ 65 years ischemic cardiopathy 3754 7.4 78.7 7.5 2461.89 2282.93 2647.08
L ≥ 65 years stroke 1679 3.3 80.8 7.6 1545.06 1441.40 1670.65
C < 65 years ischemic cardiopathy no dialysis 620 1.2 58.6 5.3 1415.44 1303.13 1573.01
I ≥ 65 years no complications 29,405 57.9 77.0 7.5 1054.64 1040.68 1068.97
H < 65 years, no complications, < 1 year or ≥ 5 years of 
diabetes
10,028 19.7 55.8 7.7 720.93 700.40 739.74
G < 65 no complications, 1–4 years of diabetes 4134 8.1 53.2 9.1 483.75 461.82 502.18
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